EP1814979A2 - Transplantation of human neural cells for treatment of neurodegenerative conditions - Google Patents
Transplantation of human neural cells for treatment of neurodegenerative conditionsInfo
- Publication number
- EP1814979A2 EP1814979A2 EP05851748A EP05851748A EP1814979A2 EP 1814979 A2 EP1814979 A2 EP 1814979A2 EP 05851748 A EP05851748 A EP 05851748A EP 05851748 A EP05851748 A EP 05851748A EP 1814979 A2 EP1814979 A2 EP 1814979A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- neural stem
- stem cell
- expanded population
- spinal cord
- neurons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000626 neurodegenerative effect Effects 0.000 title claims abstract description 32
- 238000002054 transplantation Methods 0.000 title abstract description 27
- 210000003061 neural cell Anatomy 0.000 title 1
- 210000001178 neural stem cell Anatomy 0.000 claims abstract description 336
- 210000004027 cell Anatomy 0.000 claims abstract description 261
- 238000000034 method Methods 0.000 claims abstract description 212
- 210000002569 neuron Anatomy 0.000 claims abstract description 147
- 230000001537 neural effect Effects 0.000 claims abstract description 74
- 239000003102 growth factor Substances 0.000 claims abstract description 31
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 20
- 206010056677 Nerve degeneration Diseases 0.000 claims abstract description 6
- 210000000278 spinal cord Anatomy 0.000 claims description 128
- 210000002161 motor neuron Anatomy 0.000 claims description 59
- 238000000338 in vitro Methods 0.000 claims description 47
- 210000001519 tissue Anatomy 0.000 claims description 38
- 210000000130 stem cell Anatomy 0.000 claims description 35
- 241000124008 Mammalia Species 0.000 claims description 33
- 210000003169 central nervous system Anatomy 0.000 claims description 27
- 238000001727 in vivo Methods 0.000 claims description 26
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 24
- 102100037362 Fibronectin Human genes 0.000 claims description 23
- 108010067306 Fibronectins Proteins 0.000 claims description 23
- 206010042928 Syringomyelia Diseases 0.000 claims description 23
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 23
- 208000005264 motor neuron disease Diseases 0.000 claims description 23
- 208000020431 spinal cord injury Diseases 0.000 claims description 21
- 230000001605 fetal effect Effects 0.000 claims description 19
- 230000000302 ischemic effect Effects 0.000 claims description 18
- 210000002966 serum Anatomy 0.000 claims description 18
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 17
- 208000018198 spasticity Diseases 0.000 claims description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 15
- 208000002740 Muscle Rigidity Diseases 0.000 claims description 13
- 208000006011 Stroke Diseases 0.000 claims description 13
- 230000000472 traumatic effect Effects 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 11
- 206010015037 epilepsy Diseases 0.000 claims description 11
- 208000028867 ischemia Diseases 0.000 claims description 11
- 208000023105 Huntington disease Diseases 0.000 claims description 10
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 10
- 201000010901 lateral sclerosis Diseases 0.000 claims description 10
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 9
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims description 9
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 9
- 230000002255 enzymatic effect Effects 0.000 claims description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- 230000009529 traumatic brain injury Effects 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 206010008129 cerebral palsy Diseases 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 8
- 208000000094 Chronic Pain Diseases 0.000 claims description 7
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 7
- 210000000653 nervous system Anatomy 0.000 claims description 7
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 7
- 230000006735 deficit Effects 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 108050001049 Extracellular proteins Proteins 0.000 claims description 5
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 238000010494 dissociation reaction Methods 0.000 claims description 5
- 230000005593 dissociations Effects 0.000 claims description 5
- 210000004700 fetal blood Anatomy 0.000 claims description 5
- 210000001161 mammalian embryo Anatomy 0.000 claims description 5
- 210000005259 peripheral blood Anatomy 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 2
- 229940075057 doral Drugs 0.000 claims description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 5
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims 5
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 5
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 23
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 8
- 230000012010 growth Effects 0.000 abstract description 7
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 7
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 230000003248 secreting effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 48
- 241000700159 Rattus Species 0.000 description 47
- 230000004069 differentiation Effects 0.000 description 43
- 238000002347 injection Methods 0.000 description 36
- 239000007924 injection Substances 0.000 description 36
- 210000001259 mesencephalon Anatomy 0.000 description 25
- 230000004083 survival effect Effects 0.000 description 22
- 201000010099 disease Diseases 0.000 description 18
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 17
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 17
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 230000004031 neuronal differentiation Effects 0.000 description 13
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 12
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 12
- 210000005064 dopaminergic neuron Anatomy 0.000 description 12
- 102220098893 rs878855235 Human genes 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 239000003226 mitogen Substances 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- 230000001228 trophic effect Effects 0.000 description 10
- 210000001130 astrocyte Anatomy 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 210000004884 grey matter Anatomy 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000000394 mitotic effect Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 210000004960 anterior grey column Anatomy 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 210000004498 neuroglial cell Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 7
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 7
- 101000598160 Homo sapiens Nuclear mitotic apparatus protein 1 Proteins 0.000 description 7
- 208000026072 Motor neurone disease Diseases 0.000 description 7
- 102100036961 Nuclear mitotic apparatus protein 1 Human genes 0.000 description 7
- 206010033892 Paraplegia Diseases 0.000 description 7
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 210000002932 cholinergic neuron Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000003412 degenerative effect Effects 0.000 description 7
- 230000003291 dopaminomimetic effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 6
- 102000004874 Synaptophysin Human genes 0.000 description 6
- 108090001076 Synaptophysin Proteins 0.000 description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000003050 axon Anatomy 0.000 description 6
- 230000008045 co-localization Effects 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- 208000013403 hyperactivity Diseases 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 5
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 102000004243 Tubulin Human genes 0.000 description 5
- 108090000704 Tubulin Proteins 0.000 description 5
- 238000004115 adherent culture Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 230000002964 excitative effect Effects 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003371 gabaergic effect Effects 0.000 description 5
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 210000004248 oligodendroglia Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 230000001148 spastic effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000000115 thoracic cavity Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241000283074 Equus asinus Species 0.000 description 4
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 102000008730 Nestin Human genes 0.000 description 4
- 108010088225 Nestin Proteins 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 208000007542 Paresis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000001153 interneuron Anatomy 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 210000004705 lumbosacral region Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000007659 motor function Effects 0.000 description 4
- 210000005055 nestin Anatomy 0.000 description 4
- 230000004766 neurogenesis Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000000717 sertoli cell Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 3
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 101000695522 Homo sapiens Synaptophysin Proteins 0.000 description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 208000016285 Movement disease Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 230000007012 clinical effect Effects 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 230000008175 fetal development Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006266 hibernation Effects 0.000 description 3
- 102000050055 human SYP Human genes 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 208000037906 ischaemic injury Diseases 0.000 description 3
- 230000003137 locomotive effect Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 230000001272 neurogenic effect Effects 0.000 description 3
- 239000003900 neurotrophic factor Substances 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000000063 presynaptic terminal Anatomy 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010058178 Aortic occlusion Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 2
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 2
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 208000033868 Lysosomal disease Diseases 0.000 description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 description 2
- -1 MAP2c Proteins 0.000 description 2
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 2
- 102000018656 Mitogen Receptors Human genes 0.000 description 2
- 108010052006 Mitogen Receptors Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 2
- 102000008763 Neurofilament Proteins Human genes 0.000 description 2
- 108010088373 Neurofilament Proteins Proteins 0.000 description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 102100039277 Pleiotrophin Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000032930 Spastic paraplegia Diseases 0.000 description 2
- 208000020339 Spinal injury Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 208000036815 beta tubulin Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000028436 dopamine uptake Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000005230 lumbar spinal cord Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000004973 motor coordination Effects 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 210000000461 neuroepithelial cell Anatomy 0.000 description 2
- 210000005044 neurofilament Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000007514 neuronal growth Effects 0.000 description 2
- 230000007171 neuropathology Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 108010055896 polyornithine Proteins 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000035752 proliferative phase Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- 101710154545 16 kDa protein Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 108010032947 Ataxin-3 Proteins 0.000 description 1
- 101001027553 Bos taurus Fibronectin Proteins 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
- 208000010200 Cockayne syndrome Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 101000995114 Doryteuthis pealeii 70 kDa neurofilament protein Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000693844 Homo sapiens Insulin-like growth factor-binding protein complex acid labile subunit Proteins 0.000 description 1
- 101000827703 Homo sapiens Polyphosphoinositide phosphatase Proteins 0.000 description 1
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 102000009875 Ki-67 Antigen Human genes 0.000 description 1
- 108010020437 Ki-67 Antigen Proteins 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 102100030335 Midkine Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100023591 Polyphosphoinositide phosphatase Human genes 0.000 description 1
- 102100026531 Prelamin-A/C Human genes 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102100025364 Protein bassoon Human genes 0.000 description 1
- 101710157359 Protein bassoon Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 208000021235 Schilder disease Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000001435 Synapsin Human genes 0.000 description 1
- 108050009621 Synapsin Proteins 0.000 description 1
- 241001365914 Taira Species 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000005395 beveled glass Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000003104 cytoplasmic structure Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000000268 efferent neuron Anatomy 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000910 evident toxicity Toxicity 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000000575 glycinergic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 102000052654 human GDNF Human genes 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000001926 inhibitory interneuron Anatomy 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000007654 ischemic lesion Effects 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000003078 multipolar neuron Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007557 neuronal destruction Effects 0.000 description 1
- 230000009207 neuronal maturation Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
- 229960001073 nomifensine Drugs 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229940072288 prograf Drugs 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000007441 retrograde transport Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000003270 subclavian artery Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000002182 synaptic membrane Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 208000002025 tabes dorsalis Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000011824 transgenic rat model Methods 0.000 description 1
- 230000003363 transsynaptic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/148—Transforming growth factor alpha [TGF-a]
Definitions
- the disclosed methods relate to methods of treating disorders through transplantation of cells that are uniquely beneficial for such treatment methods.
- the disclosed methods provide methods of treating neurodegenerative conditions with neural stem cells (NSCs).
- NSCs neural stem cells
- Neurodegenerative disorders are characterized by conditions involving the deterioration of neurons as a result of disease, hereditary conditions or injury, such as traumatic or ischemic spinal cord or brain injury.
- the circuitry of the spinal cord that governs contraction of skeletal muscles of the limbs involves excitatory motor neurons and inhibitory GABAergic (i.e., GABA-producing) and glycinergic (i.e., glycine-producing) inter-neurons.
- GABAergic i.e., GABA-producing
- glycinergic i.e., glycine-producing inter-neurons.
- a motor neuron is a nerve that originates from the anterior horn of the gray matter of the spinal cord. The axon of the motor neuron emerges from a segment of the spinal cord as an efferent motor fiber that innervates muscle fibers. Impulses conducted by the motor neuron stimulate the muscle fibers to contract.
- GABA gamma-amino butyric acid
- GABAergic interneurons results in dysregulation of the inhibitory tonality of the motor neuron-evoked muscle contractions. Without the control exerted by inhibitory intemeurons on excitatory neurons, an over-firing of excitatory neurons occurs leading to spastic uncontrolled contraction or uncontrolled rigidity of the muscles of the limbs. Loss of motor neurons results in flaccid paraplegia in which the subjects cannot contract the muscles and are thereby unable to move.
- GABAergic interneurons are damaged in the spinal cord includes a complication associated with a transient cross-clamping of the descending thoracic or thoracoabdominal aorta.
- Such cross-clamping is a necessary step in vascular surgery to repair aneurysms of thoracic or thoracoabdominal aorta.
- a portion of the spinal cord does not receive blood circulation and can become ischemic.
- subsequent neurodegenerative dysfunction may be expressed neurodegeneratively as paraparesis or fully-developed spastic or flaccid paraplegia.
- Neurodegeneration represents a particularly challenging biological environment for cell therapy and cell death signals present in established neurodegenerative disease (Rothstein et al., 1992; Howland et al., 2002; Turner et al., 2005) may be incompatible with graft survival, hi addition, the adult spinal cord is viewed as lacking cells and/or signals allowing regeneration (Park et al., 2002), and the majority of NSC grafting studies have shown poor or restricted differentiation (Cao et al., 2002; Yan et al., 2003; Yan et al., 2004).
- Additional challenges are presented when treating neurodegenerative diseases and conditions that are disseminated over a large area of a body, tissue, or organ, such as the entire nervous system rather than a single localized area.
- neurodegeneration involves slow death of motor neurons along the entire spinal cord as well as those neurons in motor cortex.
- neuronal destruction involves most regions of the brain and spinal cord.
- Alzheimer's disease involves most of the cerebrum.
- Even in more localized neurodegenerative diseases such as Parkinson's and Huntington's, the affected area of striatum is quite large, much larger than the grafting area that can be surgically reached.
- cell therapeutics for neurodegenerative diseases are expected to require wider grafting procedures.
- the disclosed methods include methods for treating neurodegenerative conditions.
- the disclosed methods include transplanting into a subject in need thereof NSCs, neural progenitors, or neural precursors that have been expanded in vitro such that the cells can ameliorate the neurodegenerative condition,
- the disclosed methods include identifying, isolating, expanding, and preparing the donor cells to be used as treatment of the neurodegenerative condition.
- the donor cells to be transplanted can be selected to correspond to the elements or lack thereof that contribute to the condition, its symptoms and/or its effects.
- the cells of the disclosed methods include cells that, upon transplantation, generate an amount of neurons sufficient to integrate within the neuronal infrastructure to ameliorate a disease state or condition, hi an embodiment, the disclosed methods include treating neurodegenerative diseases or conditions by transplanting multipotential neural progenitors or neural stem cells isolated from the central nervous system of a mammal and that have been expanded in vitro.
- transplantation of the expanded neural stem cells can be used to improve ambulatory function in a subject suffering from various forms of myelopathy with symptoms of spasticity, rigidity, seizures, paralysis or any other hyperactivity of muscles.
- a method of treatment can include supplying to an injured neural area, via transplantation, a suitable number of NSCs which can differentiate into a sufficient number of GABA-producing neurons and/or glycine-producing neurons to attenuate defective neural circuits, including hyperactive neural circuits.
- the disclosed methods include restoring motor function in a motor neuron disease.
- a suitable number or a therapeutically effective amount of NSCs or neural progenitors which are capable of differentiating into motor neurons can be provided to at least one area of neurodegeneration, such as a degenerative spinal cord, to restore motor function.
- the NSCs exert their therapeutic effect by replacing degenerated neuromuscular junctions.
- the NSCs exert their therapeutic effect by expressing and releasing trophic molecules which protect the neurons of the degenerating tissue so that more of them survive for longer period of time.
- NSC- derived neurons can be prompted to project into ventral roots and innervate muscle where the NSCs engage in extensive reciprocal connections with host motor neurons in subjects with degenerative motor neuron disease. Therefore, in an embodiment, NSCs from human fetal spinal cord can be grafted into the lumbar cord where these cells can undergo differentiation into neurons that form synaptic contacts with host neurons and express and release motor neuron growth factors.
- the disclosed methods include providing neural stem cells or neural progenitors that integrate with the host tissue and provide one or more growth factors to the host neurons thereby protecting them from degenerative influences present in the tissue.
- the methods include introducing a sufficient number of NSCs or neural progenitors to an area of a spinal cord such that an effective amount of at least one growth factor is secreted by the NSCs.
- the disclosed methods include providing a method for using animal models in the preclinical evaluation of stem cells for cell replacement in neurodegenerative conditions.
- the disclosed methods include increasing differentiation efficiency of transplanted NSCs into neurons. The method includes expanding highly enriched NSCs or neural progenitors in their undifferentiated state so that, upon transplantation, a sufficient number such as 20% of the cells in the graft adopts a neuronal fate.
- the disclosed methods include increasing the number of differentiated cells without increasing the number of NSCs or neural progenitors to be transplanted.
- the method includes preparing the expanded donor population in such a way that, once transplanted, the NSCs or neural progenitors continue to divide in vivo as many as ten times and without generating a tumor, thereby, effectively increasing the total number of delivered cells.
- the cells of the disclosed methods can be isolated or obtained from fetal, neonatal, juvenile, adult, or post-mortem tissues of a mammal.
- the cells of the disclosed methods can be isolated or obtained from the central nervous system, blood, or any other suitable source of stem cells that differentiate into neurons.
- the cells can also be obtained from embryonic stem cells.
- the cells include neuroepithelial cells isolated from the developing fetal spinal cord, hi certain instances, the neural precursor cells can be neural progenitors isolated from specific sub-regions of the central nervous system.
- the neural stem cells are expanded in culture, hi an embodiment, the neural precursor cells can be multipotential NSCs capable of expansion in culture and of generating both neurons and glia upon differentiation.
- the cells can be either undifferentiated, pre-differentiated or fully differentiated in vitro at the time of transplantation, hi an embodiment the cells are induced to differentiate into neural lineage.
- the cells of the disclosed methods can undergo neuronal differentiation in situ in the presence of pro-inflammatory cytokines and other environmental factors existing in an injured tissue.
- neural circuits can be treated by transplanting or introducing the cells into appropriate regions for amelioration of the disease, disorder, or condition.
- transplantation occurs into nervous tissue or non-neural tissues that support survival of the grafted cells.
- NSC grafts employed in the disclosed methods survive well in a neurodegenerative environment where the NSCs can exert powerful clinical effects in the form of delaying the onset and progression of neurodegenerative conditions or disease.
- transplantation can occur into remote areas of the body and the cells can migrate to their intended target.
- the disclosed methods can also include partial grafting of human NSCs.
- partial grafting can refer to the implantation of expanded NSCs in only a portion of an area or less than an entire area of neurodegeneration.
- partial grafting of human NSCs into the lumbar segments of spinal cord At least a portion of the effects of NSCs on degenerating motor neurons include delivery of neurotrophins and trophic cytokines to degenerating host motor neurons via classical cellular mechanisms.
- NSCs undergoing partial grafting into the lumbar segments of spinal cord using the disclosed methods have been shown in a transgenic animal model of motor neuron disease to survive, undergo extensive neuronal differentiation, promote motor neuron survival and function in the immediate area of transplantation as well as areas remote from the area of transplantation.
- the disclosed methods provide a method of treating spasticity, rigidity, or muscular hyperactivity conditions.
- the method includes isolating at least one neural stem cell from a mammal and expanding in vitro the neural stem cell to an expanded population.
- the method also includes concentrating the expanded population and introducing a therapeutically effective amount of the expanded population to at least one area of a recipient spinal cord. At least 20% of the expanded population is capable of generating neurons in the recipient spinal cord.
- the conditions derive from traumatic spinal cord injury, ischemic spinal cord injury, traumatic brain injury, stroke, multiple sclerosis, cerebral palsy, epilepsy, Huntington's disease, amyotropic lateral sclerosis, chronic ischemia, hereditary conditions, or any combination thereof.
- the neural stem cell is isolated from a source selected from the group consisting of a central nervous system, a peripheral nervous system, bone marrow, peripheral blood, umbilical cord blood and at least one embryo.
- the mammal is a developing mammal.
- the gestational age of the developing mammal is between about 6.5 to about 20 weeks.
- the neural stem cell is isolated from a human fetal spinal cord.
- expanding the neural stem cell includes culturing the neural stem cell in the absence of serum.
- expanding the neural stem cell includes exposing the neural stem cell to at least one growth factor.
- the growth factor is selected from the group consisting of bFGF, EGF, TGF-alpha, aFGF and combinations thereof.
- the therapeutically effective amount of the expanded population is capable of generating at least 1,000 GABA-producing neurons in vivo.
- the therapeutically effective amount of the expanded population is capable of generating at least 1,000 glycine-produciiig neurons in vivo.
- At least 40% of the expanded population is capable of generating neurons in the spinal cord.
- introducing the therapeutically effective amount of the expanded population includes injecting at least a portion of the therapeutically effective amount into a plurality of areas of the recipient spinal cord.
- At least 30% of the expanded population is capable of differentiating into neurons in vitro.
- a neural stem cell is provided.
- the neural stem cell is capable of treating spasticity, rigidity or muscular hyperactivity conditions.
- the neural stem cell is isolated from a mammal and expanded in vitro to an expanded population.
- the expanded population including the stem cell is concentrated and a therapeutically effective amount of the expanded population is introduced to at least one area of a recipient spinal cord. At least 20% of the expanded population is capable of generating neurons in the recipient spinal cord.
- a method of treating chronic pain is provided. The method includes isolating at least one neural stem cell from a mammal and expanding in vitro the neural stem cell to an expanded population.
- the method also includes concentrating the expanded population and introducing a therapeutically effective amount of the expanded population to at least one area of a recipient spinal cord. At least 20% of the expanded population is capable of generating neurons in the recipient spinal cord.
- the chronic pain derives from traumatic spinal cord injury, ischemic spinal cord injury, traumatic brain injury, stroke, multiple sclerosis, cerebral palsy, epilepsy, Huntington's disease, amyotropic lateral sclerosis, chronic ischemia, hereditary conditions, or any combination thereof.
- the therapeutically effective amount of the expanded population is capable of generating at least 1,000 GABA-producing neurons.
- the therapeutically effective amount of the expanded population is capable of generating at least 1,000 glycine-producing neurons.
- At least 40% of the expanded population is capable of generating neurons in the spinal cord.
- introducing the therapeutically effective amount of the expanded population includes injecting at least a portion of the therapeutically effective amount into a plurality of areas of the recipient spinal cord.
- the areas include doral horn. [0049] In an embodiment, the areas include intrathecal space.
- a neural stem cell is provided.
- the neural stem cell is capable of treating chronic pain.
- the neural stem cell is isolated from a mammal and expanded in vitro to an expanded population.
- the expanded population including the stem cell is concentrated and a therapeutically effective amount of the expanded population is introduced to at least one area of a recipient spinal cord. At least 20% of the expanded population is capable of generating neurons in the recipient spinal cord.
- a method of treating motor neuron degeneration is provided. The method includes isolating at least one neural stem cell from a mammal and expanding in vitro the neural stem cell to an expanded population.
- the method also includes concentrating the expanded population and introducing a therapeutically effective amount of the expanded population to at least one area of a recipient spinal cord. At least 20% of the expanded population is capable of generating neurons in the, recipient spinal cord.
- the motor neuron degeneration derives from traumatic spinal cord injury, ischemic spinal cord injury, traumatic brain injury, stroke, multiple sclerosis, cerebral palsy, epilepsy, Huntington's disease, amyotropic lateral sclerosis, chronic ischemia, hereditary conditions, or any combination thereof.
- the method includes isolating the neural stem cell from an area rich in at least one neuronal subtype, wherein the neuronal subtype produces a growth factor effective in ameliorating the motor deficit.
- the expanded population includes an amount of neural stem cells capable of differentiating into neurons sufficient to secrete a therapeutically effective amount of at least one growth factor.
- the method includes isolating the neural stem cell from an area rich in motor neurons.
- a neural stem cell capable of treating syringomyelia is provided.
- the neural stem cell is isolated from a mammal and expanded in vitro to an expanded population.
- the expanded population including the stem cell is concentrated and a therapeutically effective amount of the expanded population is introduced to at least one area of a recipient spinal cord. At least 20% of the expanded population is capable of generating neurons in the recipient spinal cord.
- a method of treating syringomyelia includes isolating at least one neural stem cell from a mammal and expanding in vitro the neural stem cell to an expanded population.
- the method also includes concentrating the expanded population and introducing a therapeutically effective amount of the expanded population to a syrinx of a recipient spinal cord. At least 20% of the expanded population is capable of generating neurons in the syrinx of the recipient spinal cord.
- the syringomyelia derives from traumatic spinal cord injury, ischemic spinal cord injury, traumatic brain injury, stroke, multiple sclerosis, cerebral palsy, epilepsy, Huntington's disease, amyotropic lateral sclerosis, chronic ischemia, hereditary conditions, or any combination thereof.
- the method includes isolating the neural stem cell from an area rich in at least one neuronal subtype, wherein the neuronal subtype produces a growth factor effective in ameliorating the syringomyelia.
- [0060] includes isolating the neural stem cell from an area rich in motor neurons.
- the expanded population includes an amount of neural stem cells capable of differentiating into neurons sufficient to secrete a therapeutically effective amount of at least one growth factor.
- the therapeutically effective amount of the expanded population is capable of generating at least 1,000 neurons.
- At least 100,000 neural stem cells of the expanded population are introduced to the syrinx of the recipient spinal cord.
- a neural stem cell capable of treating syringomyelia is provided
- the neural stem cell is isolated from a mammal and expanded in vitro to an expanded population.
- the expanded population including the stem cell is concentrated and a therapeutically effective amount of the expanded population is introduced to a syrinx of a recipient spinal cord. At least 20% of the expanded population is capable of generating neurons in syrinx the recipient spinal cord.
- a method of expanding in vitro at least one neural stem cell to an expanded population of neural stem cells includes dissociating neural stem cells from central nervous system tissue and providing at least one extracellular protein to a culture vessel.
- the extracellular protein includes at least about 10 ⁇ g/mL of poly-D- lysine and about 1 mg/ml fibronectin.
- the method also includes culturing the dissociated neural stem cells in the culture vessel in the absence of serum and adding to the culture vessel at least one growth factor.
- the growth factor is selected from the group consisting of bFGF, EGF, TGF-alpha, aFGF and combinations thereof.
- the method further includes passaging the cultured cells prior to confluence.
- the expanded neural stem cells are capable of differentiating into neurons.
- expanding the neural stem cell includes adding fibronectin to culture medium as a soluble factor.
- dissociating the cells and passaging the cells includes enzymatic dissociation.
- the enzymatic dissociation includes treating the cells with trypsin.
- a therapeutically effective amount of the expanded population is introduced to at least one area of a recipient nervous system to treat a neurodegenerative condition.
- Yet another advantage of the present invention is to provide a method of culturing and expanding NSCs from human fetal spinal cord to facilitate the successful engraftment of the NSCs into the lumbar cord.
- a further advantage of the disclosed methods includes providing a method of achieving a higher proportion of neuronal differentiation of a population of
- Another advantage of the disclosed method includes achieving clinical effects from partial grafting of NSCs.
- Additional features and advantages of the disclosed methods are described in, and will be apparent from, the following Detailed Description of the Invention and the figures.
- FIG. 1 Expansion of human spinal stem cells.
- a human spinal progenitor (a.k.a. NSC) line was isolated from a 7-8 week old post-mortem fetal spinal cord tissue and serially passaged for about 130 days of net culture period. At each passage, the cell number recovered at harvest was divided by the initial cell number at plating to obtain the fold-increase in cell number. Cumulative fold-increase (left Y axis) was obtained by multiplying the fold-increase at each passage. Doubling time (right Y axis) of the cells at each passage was calculated by dividing the fold-increase in cell number by the each culture period (X axis). This process was repeated three times (serial expansion 1, 2, and 3).
- FIG. 2 Morphology of expanded human spinal stem cells.
- A Phase contrast view of a fixed, unstained, expanding culture, 2Ox objective,
- B Anti-nestin antibody staining.
- FIG. 3 Characterization of differentiated cultures obtained from expanded human spinal stem cells.
- the expanded cells of passage 15-16 were differentiated for approximately 14 days in culture, fixed, and stained with various neuron-specific antibodies.
- A Tau and MAP2;
- B Type 3 beta tubulin;
- C GABA;
- D Acetylcholine transferase.
- FIG. 4 Expansion of human midbrain stem cells.
- a human midbrain progenitor (a.k.a. NSC) line was isolated from a 7-8 week old post-mortem fetal mid brain tissue and serially passaged for about 170 days of net culture period. At each passage, the cell number recovered at harvest was divided by the initial cell number at plating to obtain the fold-increase in cell number. Cumulative fold-increase (Y axis) was obtained by multiplying the fold-increase at each passage.
- FIG. 5 Dopamine uptake activity of expanded human midbrain stem cells.
- Dopamine trasporter activity (DAT) in live cells was determined from a human midbrain stem cell line and one of its clonal subline, which were differentiated for 22 or 44 days at the time of assay. The cells were incubated with radiolabeled dopamine in the presence (+) or absence (-) of the DAT inhibitor nomifensine (10 ⁇ M). Cells were washed to remove unincorporated dopamine and lysed in a scintillation cocktail. The total cellular radioactivity (dpm) was then determined using a scintillation counter.
- DAT Dopamine trasporter activity
- FIG. 6 Effect of exogenous factors on induction of neuronal differentiation and dopaminergic differentiation of human midbrain stem cell lines.
- Cryopreserved neural stem cells from two human midbrain stem cell lines (527RMB and 796RMB) were thawed and plated at a density of 40,000 cells per well in 4-well chamber slides in the presence of bFGF and allowed to proliferate for 6 days. Subsequently, bFGF was removed and cells were allowed to differentiate for additional 8 days. Cells were divided into four groups based on the timing and duration of exposure to Sertoli cell conditioned medium (SCCM, diluted 1 :1 in N2).
- SCCM Sertoli cell conditioned medium
- FIG. 7 Reduction of spasticity/rigidity and motor deficits in rats by human spinal stem cell transplantation.
- Spastic rats were produced by ischemic lesioning of the lumbar spinal cord.
- the immunosuppressant, FK506 was administrated at lmg/kg daily to both groups for the duration of the study (8 weeks). The motor coordination of individual animals was assessed by BBB scoring once every week.
- FIG. 8 Reduction of spasticity/rigidity and motor deficits in rats by human spinal stem cell transplantation.
- Spastic rats were produced by ischemic lesioning of the lumbar spinal cord.
- the immunosuppressant, FK506, was administrated at 3mg/kg daily to both groups for the duration of the study (12 weeks). The motor coordination of individual animals was assessed by BBB scoring once every week.
- FIG. 9 Effects of human NSC treatment on severity of motor neuron disease in G93A SODl rats shown with progression (A-B) as well as end-point (C-E) analysis of clinical and pathological measures in cases with live-cell (L, red) and dead-cell (control, C) grafts (blue).
- C-E End-point analysis of survival (C), time-to-disease-onset (D) and motor neuron numbers (E) in experimental and control rats.
- Inset at the bottom of (E) illustrates the difference in motor neuron survival between a representative experimental (up) and control (down) rat at 128 days of age; arrows indicate the lateral motor neuron group. Size bars: 150 ⁇ m.
- the disclosed methods are related to treating neurodegenerative conditions, m particular, the disclosed methods include methods of preparing neural stem cells for transplantation into a subject in need thereof. Preparing the cells for transplantation can include expanding in vitro a specific population of cells to a level sufficient for commercial use as a treatment for neurodegenerative conditions.
- the method of treatment of a degenerated or an injured neural area includes supplying to the area an effective number of neural stem cells sufficient to ameliorate the neurodegenerative condition.
- a neurodegenerative condition can include any Disease or disorder or symptoms or causes or effects thereof involving the damage or deterioration of neurons.
- Neurodegenerative conditions can include, but are not limited to, Alexander Disease, Alper's Disease, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia Telangiectasia, Canavan Disease, Cockayne Syndrome, Corticobasal Degeneration, Creutzfeldt- Jakob Disease, Huntington Disease, Kennedy's Disease, Krabbe Disease, Lewy Body Dementia, Machado- Joseph Disease, Multiple Sclerosis, Parkinson Disease, Pelizaeus-Merzbacher Disease, Niemann-Pick's Disease, Primary Lateral Sclerosis, Refsum's Disease, Sandhoff Disease, Schilder's Disease, Steele-Richardson-Olszewski Disease, Tabes Dorsalis or any other condition associated with damaged neurons.
- Other neurodegenerative conditions can include or be caused by traumatic spinal cord injury, ischemic spinal cord injury, stroke,
- NSCs can also refer to neural or neuronal progenitors, or neuroepithelial precursors. NSCs can be functionally defined according to their capacity to differentiate into each of the three major cell types of the CNS: neurons, astrocytes, and oligodendrocytes.
- the NSCs are multipotential such that each cell has the capacity to differentiate into a neuron, astrocyte or oligodendrocyte.
- the NSCs are bipotential such that each cell has the capacity to differentiate into two of the three cell types of the CNS.
- the NSCs include at least bipotential cells generating both neurons and astrocytes in vitro and include at least unipotential cells generating neurons in vivo.
- Growth conditions can influence the differentiation direction of the cells toward one cell type or another, indicating that the cells are not committed toward a single lineage.
- cells particularly from human CNS, are largely bipotential for neurons and astrocytes and differentiation into oligodendrocytes is minimal.
- the differentiated cell cultures of the disclosed methods may give rise to neurons and astrocytes.
- the ratio of neurons to astrocytes can approach a 50:50 ratio.
- the disclosed methods include obtaining NSCs residing in regions of a mammalian CNS such as the neuroepithelium.
- Other CNS regions from which NSCs can be isolated include the ventricular and subventricular zones of the CNS and other CNS regions which include mitotic precursors as well as post-mitotic neurons.
- the disclosed methods can employ NSCs residing in regions of a developing mammalian CNS.
- the NSCs are obtained from an area which is naturally neurogenic for a desired population of neurons.
- the desired population of cells may include the cells of a specific neuronal phenotype which can replace or supplement such phenotype lost or inactive in a neurological condition.
- a variety of different neuronal subtypes including those useful for treatment of specific neurodegenerative diseases or conditions can be obtained by isolating NSCs from different areas or regions of the CNS and across different gestational ages during fetal development. NSCs isolated from different areas or regions of the CNS and across different gestational ages are used for optimal expansion and neuronal differentiation capacity.
- One of the hallmarks of the mammalian CNS is the diversity of neuronal subtypes.
- a single population of NSCs may spontaneously generate only a few distinct neuronal subtypes in culture.
- the cells from a particular fetal gestational age may establish the physiological relevance of the cultured cells.
- the cells to be transplanted into subjects are derived from the human fetal counterpart of the injured neural area.
- NSCs are isolated from human fetal CNS regions at gestational ages of between about 6.5 to about 20 weeks.
- cells from a fetal spinal cord are isolated at a gestational age of about 7 to about 9 weeks. It should be appreciated that the proportion of the isolatable neural stem cell population can vary with the age of the donor. Expansion capacity of the cell populations can also vary with the age of the donor. Such regional and temporal specificity of NSCs indicates that NSCs behave as fate-restricted progenitors and not as blank cells or a single population of cells.
- the proportion of the population in vitro including GABA-producing neurons is generally constant at about 5-10%.
- the NSCs of the ventral midbrain are distinct from the NSCs obtained from the spinal cord at the same gestational stage, hi particular, the NSCs from the ventral midbrain exclusively give rise to tyrosine-hydroxylase- expressing dopaminergic neurons, whereas NSCs from the spinal cord exclusively generate acetylcholine-producing cholinergic neurons. Both cell types, however, simultaneously generate the more ubiquitous gluamate- and GABA-producing neurons. Therefore, in an embodiment, the disclosed methods include obtaining NSCs from the ventral midbrain to treat conditions ameliorated or attenuated, at least in part, by the implantation of tyrosine-hydroxylase-expressing dopaminergic neurons. The disclosed methods further include obtaining NSCs from the spinal cord to treat neurodegenerative conditions ameliorated or attenuated, at least in part, by the implantation of acetylcholine-producing cholinergic neurons.
- an embodiment of the disclosed methods includes the use of NSCs derived from an area such as the ventral midbrain in which neurogenesis of dopaminergic neurons is substantial.
- the NSCs can be obtained at a gestational age of human fetal development during which neurogenesis of dopaminergic neurons is substantial.
- the disclosed methods include obtaining NSCs from the ventral midbrain derived at a gestational age of about 7 to about 9 weeks to treat movement disorders.
- an embodiment of the disclosed methods includes the use of NSCs derived from an area such as the spinal cord in which neurogenesis of ventral motor-neurons is substantial and obtained at a gestational age of human fetal development during which neurogenesis of ventral motor-neurons is substantial. Accordingly, in an embodiment, NSCs are isolated from the spinal cord at a gestational age of about 7 to about 9 weeks to treat motor neuron diseases.
- NSCs from various areas of the spinal cord such as cervical, thoracic, lumbar, and sacral segments can be used interchangeably to be implanted and to treat locations other than the corresponding origin of the NSCs.
- NSCs derived from cervical spinal cord can be used to treat spasticity and/or rigidity by transplanting the cells into the lumbar segments of a patient.
- NSCs can also be isolated from post-natal and adult tissues. NSCs derived from post-natal and adult tissues are quantitatively equivalent with respect to their capacity to differentiate into neurons and glia, as well as in their growth and differentiation characteristics. However, the efficiency of in vitro isolation of NSCs from various post-natal and adult CNS can be much lower than isolation of NSCs from fetal tissues which harbor a more abundant population of NSCs. Nevertheless, as with fetal- derived NSCs, the disclosed methods enable at least about 30% of NSCs derived from neonatal and adult sources to differentiate into neurons in vitro. Thus, post-natal and adult tissues can be used as described above in the case of fetal-derived NSCs, but the use of fetal tissues is preferred.
- neuronal subtypes can be obtained from manipulation of embryonic stem cells expanded in culture.
- specific neuronal subtypes based on the disclosed methods, can be isolated and purified from other irrelevant or unwanted cells to improve the result, as needed, and can be used for treatment of the same neurodegenerative conditions.
- the NSCs in the disclosed methods can be derived from one site and transplanted to another site within the same subject as an autograft. Furthermore, the NSCs in the disclosed methods can be derived from a genetically identical donor and transplanted as an isograft. Still further, the NSCs in the disclosed methods can be derived from a genetically non-identical member of the same species and transplanted as an allograft. Alternatively, NSCs can be derived from non-human origin and transplanted as a xenograft. With the development of powerful immunosuppressants, allograft and xenograft of non-human neural precursors, such as neural precursors of porcine origin, can be grafted into human subjects.
- a sample tissue can be dissociated by any standard method, hi an embodiment, tissue is dissociated by gentle mechanical trituration using a pipet and a divalent cation-free saline buffer to form a suspension of dissociated cells. Sufficient dissociation to obtain largely single cells is desired to avoid excessive local cell density.
- the culture methods can be optimized to achieve long-term, stable expansion of an individual cell line of NSCs from different areas and ages of CNS development while maintaining their distinct progenitor properties.
- NSCs NSCs
- the extracellular matrix proteins can include poly- D-lysine, poly-L-lysine, poly-D-ornithine, poly-L-ornithine, fibronectin and combinations thereof.
- extracellular matrix proteins can include various isotypes, fragments, recombinant forms, or synthetic mimetics of fibronectin, lamin, collagen, and their combinations.
- the disclosed methods can include any other suitable substance that is able to promote effective cell adhesion so that each individual cell is adhered to the culture substrate during the entire duration of the culture without being cytotoxic or retarding the cell division.
- extracellular matrix proteins can be effective in promoting cell adhesion
- different amino acid polymers such as poly-L/D-ornithine or poly-L/D- lysine
- concentrations of polymer can be within a range of between about 0.1 ⁇ g/mL and about 1 mg/niL.
- 100 ⁇ g/ml of poly-D-lysine is dissolved in 0.0 IM HEPES buffer or water at neutral pH and applied to a culture vessel. The culture vessel is incubated for 1 hour at room temperature. The culture vessel is then thoroughly rinsed with water and dried prior to use.
- the disclosed methods can also include double-coating the culture vessels with an extracellular matirx protein, hi an embodiment, the culture vessel is treated with fibronectin or a fibronectin derivative following the application of poly- L/D-ornithine or poly-L/D-lysine described above, m an embodiment, fibronectin protein prepared from human plasma is used. It should be appreciated, however, that any other suitable form or source of fibronectin protein can be used such as porcine or bovine fibronectin, recombinant fibronectin, fragments of fibronectin proteins, synthetic peptides, and other chemical mimetics of fibronectin. In an embodiment, between about 0.1 ⁇ g/mL to about 1 mg/mL of fibronectin can be applied.
- the culture vessel is treated with 100 ⁇ g/mL of poly-D-lysine for a period sufficient to allow the extracellular protein to bind to and coat the culture vessel. Such a time period can be for about five minutes to about three hours.
- the culture vessel can be subsequently washed with water. After air-drying the culture vessel, the vessel can be treated with about 25 mg/ml fibronectin for approximately five minutes to several hours at room temperature or about 1 mg/ml fibronectin for approximately 1 hour to several days at 37 0 C. Subsequently, the fibronectin can be removed and the culture vessel can be washed at least once or stored in PBS until use.
- fibronectin can be added into the growth medium as a soluble factor supplied directly to the cells.
- NSCs can be expanded by adding 1 ⁇ g/mL of fibronectin into the growth medium in addition to, or instead of, treatment of the culture vessels with fibronectin.
- Supplying the attachment protein into the growth medium as a soluble factor at the time of cell plating is particularly advantageous for large commercial-scale culturing of NSCs due to the relatively short shelf-life of fibronectin-coated vessels.
- This method is also useful for manufacturing a neural stem cell line requiring substantially exact conditions and reproducibility such as required under cGMP protocols and for manufacturing the neural stem cell line for therapeutic use.
- the isolated NSCs are added to the cluture vessel at a density of about 1,000 to about 20,000 cells per square cm. Such a density contributes to even dispersion and adhesion of individual cells in the culture vessel, avoiding localized concentrations of cells, to enriched the culture for NSCs.
- NSCs are expanded in the absence of serum.
- the NSCs are cultured in a defined, serum-free medium to avoid exposure of the NSCs to concentrations of serum sufficient to destabilize the mitotic and differentiation capacity of NSC.
- exposure of the NSCs to certain growth factors such as leukemia inhibitory factor (LIF) or ciliary neurotrophic factor (CNTF) can also destabilize NSCs and should be avoided.
- LIF leukemia inhibitory factor
- CNTF ciliary neurotrophic factor
- Mitogens can be added to the culture at any stage of the culture process to enhance the growth of the NSCs.
- Mitogens can include basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), transforming growth factor-alpha (TGFa), and combinations thereof.
- bFGF basic fibroblast growth factor
- aFGF acidic fibroblast growth factor
- EGF epidermal growth factor
- TGFa transforming growth factor-alpha
- NSCs of the disclosed methods can be grown and expanded in at least two different culture forms.
- One form of culture includes an aggregated form, commonly referred to as a clustered, aggregated form referred to as a suspension culture.
- Another form of culture includes a dispersed, non-aggregated form referred to as an adhesion culture.
- the cells form a monolayer in which individual cells initially contact the culture substrate directly. Eventually, after a period of incubation, the cells can sporadically form clusters, wherein at least one additional layer of cells is formed on the bottom layer, even as the cells in the bottom layer are individually adhered to the substrate.
- clustering especially occurs when the culture is inoculated at high cell density or allowed to reach high cell density, which, in an embodiment, is minimized for optimal expansion of NSCs or progenitor cells or for optimal maintenance of the multipotential capacity of the NSCs.
- human NSCs are enabled to divide in less than about four days per cell division.
- the dispersed adherent culture of NSCs of the disclosed methods divide to generate daughter cells, each retaining their multipotential capacity.
- the dispersed adherent culture of NSCs of the disclosed methods includes an expansion capacity of at least 20 cell doublings in the absence of substantial differentiation. Most NSCs can be expanded beyond at least 50 cell doublings before losing their neurogenic potential.
- the NSCs expanded in the dispersed adherent culture of the disclosed methods demonstrate enhanced neuronal differentiation, giving rise, in an embodiment, to at least about 30% neuronal differentiation. In many cases, at least 50% of NSCs differentiate into neurons.
- the dispersed, adherent form of culture is a more preferred form of culture, the different culture methods may allow isolation of innately distinct cell populations with differing differentiation potentials either in vitro or in vivo.
- the present method also allows clonal isolation of NSCs from a variety of sources without genetic modification or inclusion of feeder cells.
- a very low number preferably less than 1000 cells per square centimeter of cells, may be seeded in a cell culture dish prepared as described above.
- the cells can form well-isolated colonies.
- the colonies may be grown to a desired size such as at least about 250 to about 2000 cells, hi an embodiment, at least one colony of cells is manually picked and inoculated individually to a fresh cell culture dish such as a multi-well plate.
- Isolated clonal populations may be expanded by serial passaging and used to establish multiple neural stem cell lines. Many such clonal cell lines have been isolated from various areas of the human CNS including spinal cord, midbrain, and hindbrain. Clonal cell lines are useful to enrich for a particular cell phenotype such as a higher proportion of neuronal subtypes. For example, clonal cell lines enriched for tyrosine hydroxylase-expressing dopaminergic neurons, GABAergic neurons, cholinergic neurons and neurons of other specific phenotypes can be isolated with the disclosed methods.
- either a polyclonal or a monoclonal neural stem cell line can be induced to be further enriched for a particular subtype of neurons.
- a number of growth factors, chemicals, and natural substances have been screened to identify effective inducers of particular neurons such as tyrosine hydroxylase- expressing dopaminergic neurons and acetylcholine-producing cholinergic neurons from NSCs of midbrain or spinal cord.
- the factor or chemical or combination thereof can be introduced during the mitotic phase and/or the differentiation phase of the NSCs.
- a neural stem cell line for a dopaminergic phenotype is further enriched as a donor population to treat Parkinson's disease.
- Various neuronal subtypes can be obtained from isolation of stem cells having a desired differentiation pattern in vitro. In vitro results can be substantially reproduced in vivo. This means that the potential efficacy of the stem cells in vivo can be predicted by the differentiation pattern of the stem cells in vitro.
- NSCs Upon injection into live post-natal subjects, NSCs, in either an undifferentiated or pre- differentiated state, produces to a large extent an in vivo differentiation pattern observed in vitro.
- NSC giving rise to tyrosine hydroxylase-producing neurons in vitro also generate tyrosine hydroxylase-producing neurons in vivo.
- NSCs not giving rise to tyrosine hydroxylase-producing neurons constitutively in vitro do not produce tyrosine hydroxylase-producing neurons in vivo.
- NSCs are plastic. Such plastic nature of NSCs is a characteristic of their multipotentiality and, as such, this plasticity can be used to identify phenotype- inducing agents and conditions which can be further combined with an NSC population to re-direct its properties.
- such re-programming includes treating NSCs from a spinal cord tissue to obtain enhanced expression of motor neuron phenotypes.
- the treatment conditions include co-culturing NSCs or their differentiated cells with various muscle cells or peripheral nervous system-derived cells such as neural crest cells or ganglionic neurons.
- NSCs can also be treated with cocktails of molecules known to be expressed and produced in motor neurons or in the spinal cord to enhance NSC expression of motor neuron phenotypes.
- NSCs are treated with molecules such as lithium, GDNF, BDNF, pleiotrophin, erythropoeitin, conditioned media from cells such as Sertoli cells, or any other suitable chemicals or cells obtained by screening or combinations thereof.
- molecules such as lithium, GDNF, BDNF, pleiotrophin, erythropoeitin, conditioned media from cells such as Sertoli cells, or any other suitable chemicals or cells obtained by screening or combinations thereof.
- the NSCs of the disclosed methods can include pre-differentiated cells for transplantation.
- pre-differentiated cells for transplantation For maximum yield of the cells and for simplicity of the procedure, a confluent culture is harvested for transplantation which comprises primarily a population of undifferentiated cells. It should be appreciated, however, that a minor population of cells just starting to differentiate spontaneously can also exist due to the increased cell density.
- passaging NSCs includes harvesting or detaching the cells from a stubstrate.
- the disclosed methods include harvesting or detaching the cells from a stubstrate using at least one enzyme. Enzymatic treatment can be avoided when the cell cycle time of the NSCs is short enough to deactivate the mitogen receptors on the cell surface. However, the cell cycle time of human NSCs is much longer than rodent NSCs such that human NSCs are not as sensitive to enzymatic treatment. Thus, in the disclosed methods, enzymatic treatment is used for harvesting NSCs derived from a human. Although the human NSCs can become temporarily refractory to mitogen in the presence of enzymatic treatment, repeated deactivation of the mitogen receptors can lead to a decreased proportion of NSCs.
- the cells upon harvesting of the cells, the cells are concentrated by brief centrifugation.
- the cells can be further washed and re- suspendend in a final, clinically usable solution such as saline, buffered saline, or, alternatively, be re-suspendend in a storage or hibernation solution.
- the cells can be re-suspendend in a freezing medium such as media plus dimethylsulfoxide, or any other suitable cryoprotectant, and frozen for storage.
- the hibernation solution is formulated to maintain the viability of live cells for a prolonged period of time
- the storage solution can be adapted to be used for shipping live cells in a ready-to-use formulation to a transplantation surgery site for immediate use.
- Suitable conditions for shipping live cells to a distant site also includes an insulation device that can maintain a stable temperature range between about O 0 C and about 2O 0 C for at least 24 hours.
- Live cells stored at between about O 0 C and about 8 0 C for about 24 hours to about 48 hours are engraftable for treatment of a disease or condition.
- the cells are concentrated in a solution such as the clinically usable, hibernation or freezing solutions described above, hi an embodiment, the cells are concentrated to an appropriate cell density which can be the same or different from the cell density for administration of the cells, hi an embodiment, the cell density for administration can vary from about 1,000 cells per microliter to about 1,000,000 cells per microliter depending upon factors such as the site of the injection, the neurodegenerative status of the injection site, the minimum dose necessary for a beneficial effect, and toxicity side-effect considerations. In an embodiment, the disclosed methods include injecting cells at a cell density of about 5,000 to about 50,000 cells per microliter.
- the volume of media in which the expanded cells are suspended for delivery to a treatment area can be referred to herein as the injection volume.
- the injection volume depends upon the injection site and the degenerative state of the tissue. More specifically, the lower limit of the injection volume can be determined by practical liquid handling of viscous suspensions of high cell density as well as the tendency of the cells to cluster.
- the upper limit of the injection volume can be determined by limits of compression force exerted by the injection volume that are necessary to avoid injuring the host tissue, as well as the practical surgery time.
- the cells are concentrated to a density of about 1,000 to about 200,000 cells per microliter. In an embodiment, about 5,000 to about 50,000 cells per microliter have been used for effective engraftment. In another embodiment, about 10,000 to 30,000 cells per microliter is used.
- the cells can be delivered to a treatment area suspended in an injection volume of less than about 100 microliters per injection site.
- an injection volume of 0.1 and about 100 microliters per injection site can be used.
- Any suitable device for injecting the cells into a desired area can be employed in the disclosed methods.
- a syringe capable of delivering sub-microliter volumes over a time peirod at a substantially constant flow rate is used.
- the cells can be loaded into the device through a needle or a flexible tubing or any other suitable transfer device.
- the desired injection site for treatment of a neurodegenerative condition includes at least one area of the spinal cord
- the cells are implanted into at least one specific segment or region of the spinal cord such as the cervical, thoracic or lumbar region of the spinal cord, hi the lumbar region, for example, only five pairs of nerve roots traverse the bony canal of vertebrae with each pair of nerve roots exiting the spine at each lumbar level distributed over a wide area. Due to a lower density of nerve roots in the lumbar region of the spinal cord, the lumbar region is particularly well-suited for providing a safe site for injection of cells, hi an embodiment, the cells are implanted in the intermediate zone of the spinal cord parenchyma.
- the cells are injected at between about 5 and about 50 sites. In an embodiment, the cells are injected at between about 10 to about 30 sites on each side of the cord. At least two of the sites can be separated by a distance of approximately 100 microns to about 5000 microns, hi an embodiment, the distance between injection sites is about 400 to about 600 microns. The distance between injections sites can be determined based on generating substantially uninterrupted and contiguous donor cell presence throughout the spinal segments and based on the average volume of injections demonstrated to achieve about 2-3 month survival in animal models such as rats or pigs.
- the cells are injected along both sides of the midline of the spinal cord to span the length of at least several lumbar segments useful for treating a symptom such as spasticity/rigidity or motor neuron survival.
- a symptom such as spasticity/rigidity or motor neuron survival.
- the actual number of injections in humans can be extrapolated from results in animal models.
- the target site of injection is the gray matter of the spinal cord.
- the needle tip can be positioned to deposit the NSCs at specfic levels of lamina.
- the NSCs are delivered to the area encompassing lamina V-VII.
- the NSCs can be delivered to or near the dorsal horn of the gray matter of various spinal segments, from cervical to lumbar, in order to treat neuropathic pain or chronic pain.
- the NSCs can be delivered to or near the ventral horn of the gray matter of various spinal segments from cervical to lumbar in order to treat motor neuron diseases such as ALS.
- the cells of the disclosed methods can generate large numbers of neurons in vivo.
- the NSCs When the NSCs are not overtly pre-differentiated prior to transplant, the NSCs can proliferate up to two to four cell divisions in vivo before differentiating, thereby further increasing the number of effective donor cells.
- the neurons Upon differentiation, the neurons secrete specific neurotransmitters.
- the neurons secrete into the mileu surrounding the transplant in vivo growth factors, enzymes and other proteins or substances which are beneficial for different conditions. Accordingly, a variety of conditions can be treated by the disclosed methods because of the ability of the implanted cells to generate large numbers of neurons in vivo and because the neurodegenerative conditions may be caused by or result in missing elements including neuron-derived elements. Therefore, subjects suffering from degeneration of CNS tissues due to lack of such neuron-derived elements, such as growth factors, enzymes and other proteins, can be treated effectively by the disclosed methods.
- Conditions responding to growth factors, enzymes and other proteins or substances secreted by the implanted neurons include hereditary lysosomal diseases such as Tay-Sach's disease, Niemann-Pick's disease, Batten's disease, Crabb's disease, ataxia, and others.
- the disclosed methods of treatment include implanting the cells expanded in vitro which can replace damaged or degenerated neurons, provide an inhibitory or stimulatory effect on other neurons, and/or release trophic factors which contribute to the regeneration of neurons.
- An embodiment includes supplying additional motor neurons as replacement of damaged or degenerated neurons.
- the disclosed methods include providing sufficient neural infrastructure within the syrinx of the spinal cord to fill the cavitation. Neural infrastructure is sufficient if it is capable of slowing the enlargement of the syrinx associated with syringomyelia resulting from traumatic spinal injury, hereditary conditions or any other cause. It should be appreciated that providing sufficient neural infrastructure also helps relieve further complications arising from degenerating spinal cord.
- NSCs are therapeutic for a given disease.
- the types of neuronal populations affected in different diseases may be different. Therefore, a therapeutically effective donor population of NSCs contributes to replacing the lost neural element.
- treatment of spasticity, seizure, movement disorders, and other muscular hyperactivity disorders can include providing a therapeutically effective amount of cells capable of differentiating into inhibitory neurons producing GABA or glycine. Distinct populations of NSCs can be assessed in vitro by examining the differentiated neuronal phenotype.
- the in vitro differentiation pattern is then used to predict the efficacy of the cells to produce the appropriate phenotype in vivo, not only in terms of an appropriate neurotransmitter phentoype, but also in terms of an appropriate morphology, migration, and other phenotypic characteristics of neurons.
- NSCs are implanted that are capable of generating the neuronal subtype corresponding to the damaged or destroyed neuronal subtypes associated with the etiology of the symptoms.
- hyperactivity of excitatory circuits in subjects can be caused by hereditary conditions or neuronal injury from spinal trauma, thoracic/thoracoabdominal aorta surgery, stroke, epilepsy, brain trauma, Huntington's disease, bladder incontinence, hyperactive bowel movement and any other uncontrolled contraction of muscles arising from injury or hereditary conditions.
- Spasticity, seizures, or other hyperactivity occurs in the brain as opposed to the spinal cord due to a number of different etiological origins.
- Focal epilepsy for example, is thought to arise from disregulated hyperactivity due to a lack of GABA exerting tonal control over the circuitry.
- disclosed methods include providing inhibitory neurotransmitters such as GABA or glycine in the affected areas by transplantation of in vitro expanded NSCs.
- a number of NSCs which are capable of differentiating into inhibitory neurons, such as GABA-producing or glycine-producing neurons are generated in vivo to be transplanted to attenuate at least one hyperactive neural circuit associated with spasticity, seizure, and other neuronal hyperactivity.
- the disclosed methods can, therefore, be applied to treat epilepsy and similar conditions of seizures.
- the disclosed methods can also be applied to treat paresis, paralysis, spasticity, rigidity or any other motor, speech, or cognitive symptoms arising from cerebral ischemia.
- Cerebral ischemia can occur as a result of a stroke event in the brain or from a heart attack in which the blood circulation to the brain is interrupted for a significant period of time. It is, thus, analogous to the spinal cord ischemia described above.
- Some stroke subjects develop seizures of central origin as well as other deficits such as memory loss, paralysis, or paresis. These deficits from cerebral ischemia are also likely due to selective loss of inhibitory interneurons in hippocampus and/or other brain areas.
- the disclosed methods can be applied to treat stroke subjects suffering from paresis, paralysis, spasticity, or other motor, speech, and cognitive symptoms.
- the disclosed methods include providing neuronal implantation to exert sufficient trophic influence to slow the loss of motor neurons.
- the disclosed methods facilitate the ability of the transplanted NSCs to secrete trophic molecules which can be delivered to degenerating motor neurons under conditions of optimal biovailability.
- trophic molecules include exocitosed superoxide dismutases such as superoxide dismutase (SODl), lysosomal enzymes, and non-proteinatious molecules such as cell-produced antioxidants.
- trophic factors secreted by the transplanted cells can include global cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), vascular epidermal growth factor (VEGF), pleiotrophin, vascular endothelial growth factor (VEGF), erythropoetin, midkine, insulin, insulin-like growth factor 1 (IGF-I), and insulin-like growth factor 2 (IGF-2) or any other beneficial trophic element.
- GDNF global cell-derived neurotrophic factor
- BDNF brain-derived neurotrophic factor
- VEGF vascular epidermal growth factor
- VEGF vascular endothelial growth factor
- IGF-I insulin-like growth factor 1
- IGF-2 insulin-like growth factor 2
- Another factor that contributes to the ability of the disclosed methods to treat a wide range of neurodegenerative conditions includes the ability of the NSC-differentiated cells to migrate extensively along existing neuronal fibers.
- Migration of the grafted cells results in global distribution and integration of donor neurons and/or glia and global or dispersed supply of the therapeutic element secreted by such cells.
- the cells of the disclosed methods are effective delivery vehicles for therapeutic proteins and substances.
- the disclosed methods include transplanting the cells into various sites within the nervous system including the CNS parenchyma, ventricles, the subdural, intrathecal and epidural spaces, peripheral nervous system sites as well as into areas outside of the nervous system including the gut, muscle, endovascular system, and subcutaneous sites.
- fibronectin for 1 hour at room temperature was used. Sometimes, lmg/ml fibronectin for 18 hours at 37 0 C was used.
- Culture media consisting of N2 (DMEM/F12 plus insulin, transferrin, selenium, putrescine, and progesterone) was supplemented with lhuman recombinant basic fibroblast growth factor (bFGF).
- bFGF basic fibroblast growth factor
- a range of 0.1ng/ml - 100ng/ml can be used, hi an embodiment, optimally, 10ng/ml of bFGF is used.
- the resulting initial culture consists of post-mitotic neurons and proliferative NSCs in a monolayer. Subsequently, after approximately five to about twenty days in culture, the dividing, nestin-positive, NSCs dominate the culture over the non-dividing neurons or the slowly-dividing glia. Under these culture conditions, NSCs are selectively favored for expansion.
- the expanding NSC population is passaged by mild enzymatic treatment, such as using trypsin.
- the cells are cultured in media free of serum or substantially free of serum. Although low concentration of serum may be tolerated by the cells, it is best to avoid exposing the cells to serum since serum contains many cytokines such as LIF and CNTF which promote glial differentiation of the NSCs.
- human NSCs can be expanded beyond 10 18 -fold increase in population while maintaining their growth and differentiation properties.
- the cells can be expanded reproducibly. As shown in FIG. 1, serial passaging of the cells have been repeated three times with reproducible growth curve and doubling time of the cells. During the expansion, almost all cells express nestin, the in vivo marker of mitotic neuroepithelial cells, and are absent of antigens of differentiated neurons and glia such as type 3-beta tubulin and GFAP.
- the cells are also negative by immunostaining for PSA-NCAM, a possible marker of committed neuronal progenitors, 04 and GaIC, markers of oligodendrocytes, and RC2, a marker of radial glia.
- PSA-NCAM a possible marker of committed neuronal progenitors
- 04 and GaIC markers of oligodendrocytes
- RC2 markers of radial glia.
- the cultures can be differentiated by withdrawal of the mitogen in the culture such as bFGF. Differentiation of NSCs ensues within about 1-3 days after the removal of mitogen, and distinct heterogeneous cell morphologies are apparent.
- the mitogen in the culture such as bFGF.
- Differentiation of NSCs ensues within about 1-3 days after the removal of mitogen, and distinct heterogeneous cell morphologies are apparent.
- neuron-specific antigens such as MAP2c, tau, and type III beta- tubulin, can be visualized by immunostaining.
- MAP2c neuron-specific antigens
- tau elongated, fasciculated axonal processes are evident throughout the culture along with clear polarization of subcellular protein trafficking.
- synaptic proteins such as synapsin and synaptophysin
- Additional feeder layer of astrocytes can be provided to further promote long-term maturation of the neurons.
- differentiation of human spinal NSCs generates mixed cultures of neurons and glia wherein the neurons robustly express neuron-specific antigens such as tau, MAP2ab (A) and type3 beta tubulin (B) and comprises approximately 50% of the culture.
- the culture spontaneously generates long, bundled, axon cables that stretch for several centimeters.
- significant proportion of the neurons are GABAergic.
- Cholinergic motor neurons are also present in the culture (FIG. 3D). Presence of significant GABA neurons in culture predicts usefulness of the human spinal NSCs for treating various neurological conditions caused by decreased GABA production in certain circuitry. Likewise, presence of cholinergic neurons demonstrates that the human spinal NSCs are capable of motor neuron differentiation and predicts their usefulness for treating various motor neuron diseases caused by gradual degeneration of motor neurons.
- the NSCs are expanded with or without further phenotype-enhancing conditions, harvested, and injected into a neural area of deficiency.Example 3. Expansion of Human Midbrain Neural Stem/Progenitor Cells. One midbrain tissue of fetal gestational age 7-8.5 week is obtained.
- NSCs from the midbrain tissue are obtained as described in Example 1.
- the cells are serially passaged over 160 days of net culture period and the resultant expansion is shown in FIG4.
- the NSCs stably maintain their multipotipotentiality and neurogenic potential as well as their differentiation potential to give rise to dopaminergic neurons.
- Dopaminergic neurons are assessed by neuronal expression of tyrosine hydroxylase (TH) and dopamine transporter (DAT).
- TH tyrosine hydroxylase
- DAT dopamine transporter
- DAT expression is a marker of dopamine-producing neurons.
- DAT expression in neurons can be assessed by measuring its function to transport radiolabeled dopamine across the synaptic membrane of differentiated neurons in culture.
- DAT function in cultures from differentiated human midbrain NSCs and monoclonally derived human midbrain NSCs are assessed by the radiolabelled dopamine uptake assay (FIG. 5).
- the assay result shows robust functional dopaminergic activity of human midbrain NSCs.
- dopaminergic phenotype can be enriched by isolated monoclonal population of NSC which is particularly inclined to give rise to higher proportion of dopaminergic neurons upon differentiation (FIG. 5).
- NSCs generating enriched dopaminergic neurons is particularly useful for treatment of parkinson's disease.
- NSCs pre-programmed at the time of isolation from the tissue for enhanced differentiation for a specific phenotype can be used to isolate other specific desired neurons, such as forebrain cholinergic neurons useful for treatment of Alzheimer's disease, spinal cholinergic neurons useful for treatment of motor neuron diseases such as ALS, serotonergic neurons useful for treatment of depression, and GABAergic neurons useful for treatment of epilepsy and Hungtinton's disease.
- specific desired neurons such as forebrain cholinergic neurons useful for treatment of Alzheimer's disease, spinal cholinergic neurons useful for treatment of motor neuron diseases such as ALS, serotonergic neurons useful for treatment of depression, and GABAergic neurons useful for treatment of epilepsy and Hungtinton's disease.
- Human midbrain NSCs/progenitors can be differentiated as described in Example 2. During the mitotic period of the NSCs or during their differentiation, the proportion of desired phenotype can be enriched by treatment of the culture with various exogenous factors. An example of such factors capable of enriching dopaminergic phenotype from the human midbrain NSCs is demonstrated by the conditioned media from Sertoli cells, as illustrated FIG. 6 A and 6B.
- cryopreserved neural stem cells were thawed and plated at a density of 40,000 cells per well in 4-well chamber slides in the presence of mitogen and allowed to proliferate for 6 days, at which time mitogen was removed and cells were allowed to differentiate for 8 days.
- Cells were divided into four groups based on the timing and duration of exposure to Sertoli cell conditioned medium (SCCM, diluted 1:1 in N2a). One group was exposed to SCCM during proliferation and differentiation (condition 1); a second was exposed during proliferation only (condition 2); a third was exposed during differentiation only (condition 3); and a fourth was not exposed to SCCM (control or cont).
- SCCM Sertoli cell conditioned medium
- MAP2 MAP2ab subtypes
- TuJl neuron-specific ⁇ -tubulin
- Pel-Freez tyrosine hydroxylase
- Immunostained cells were counted using a 4Ox objective, and at least three fields were counted for each well. Few or no GF AP+ or GaIC+ cells were detected upon analysis of cells maintained under any condition, so these antigens were excluded from the analysis.
- 566SC cells were too dense to quantitate after maintenance under the conditions described and were not included in the final analysis.
- the analysis illustrates that the human midbrain NSCs can be influenced by treatment with exogenous factors to search for useful protein factor or chemicals to further enrich for dopaminergic neurons.
- novel synthetic/natural chemical and protein factors can be effectively screened by using human NSCs to obtain particularly useful populations for treatment of specific indication such as Parkinson's disease.
- Example 5 Treatment of Spasticity and Rigidity in Rats by Transplantation of Human Spinal Neural Stem/Progenitor Cells.
- BBB score of 0-4 are anesthetized with 1.5-2% halothane in room air and placed into a spinal unit apparatus.
- a partial laminectomy of Thl l-L2 vertebra is then performed.
- a glass capillary having a tip diameter of 80-100 ⁇ m is connected to a pressure-controlled microinjector. Rats are injected with 0.5 ⁇ l of cell suspension containing 5,000, 10,000, 15,000 or 20,000 human neural stem/progenitor cells per injection. Each rat receives a total of 6-8 injections on each side of the spinal cord (left and right), evenly distributed between exposed L2-L6 segments.
- the center of the injection is targeted into central gray matter (laminae V-VII) (distance from the dorsal surface of the spinal cord at L3 level: 1 mm).
- the incision is cleaned with 3% H 2 O 2 and a penicillin/streptomycin mixture and closed in 2 layers. Rats are then allowed to recover.
- rats are anesthetized with pentobarbital (40 mg/kg; i.p.) and transcardially perfused with heparinized saline for 1- 2 min followed by 4% paraformaldehyde in 0.1M phosphate buffer (PB).
- PB phosphate buffer
- the spinal cords are dissected and postfixed in the same fixative overnight at 4 0 C.
- spinal cord tissue is cryoprotected in a graded sucrose solution (10, 20 and 30%) for a total of three days. Frozen coronal, parasagittal or horizontal spinal cord sections (10-30 ⁇ m) are then cut.
- the total numbers of grafted neurons immunoreactive for the human nuclear NUMA antibody are estimated using stereological, unbiased and systematic sampling. Each tenth, previously-stained section taken from L2-L6 spinal segments is used for stereological quantification after applying fractionator sampling scheme.
- the optical images (1 ⁇ m thick) are obtained by Leica DMLB microscope using a 10Ox oil immersion objective with numerical aperture 1.3. The optical images are captured using a digital camera (Olympus) and ImagePro software (Media Cybernetics) supplied with a StagePro-controlled motorized Z stage (Media Cybernetics).
- NUMA-positive cells show co-localization with GFAP antibody. These cells are typically localized at the periphery of the grafts.
- the stereological estimation of NUMA-positive cells shows an average of 75,460 ⁇ 5,697 persisting grafted cells within individual grafts. This represents an average of 3-3.6 times more cells than originally injected.
- the cell-cycle antigen, Ki67 is a marker of actively mitotic cells. Staining of spinal cord sections at two or seven weeks after grafting show hKi67 immunoreactivity only at two weeks after grafting. Only occasionally (1-2 cells /10 sections) are cells Ki67-positive at seven weeks of survival.
- volume reconstruction of transplanted L3-L5 segments is performed by using images taken from 40 ⁇ m-thick serial spinal cord sections stained with MOC antibody and DAPI (total number of 150-200 sections).
- Three-dimensional graft reconstruction shows a well recognized rostrocaudally orientated MOC-positive implant distributed within the range of gray matter.
- the functional effect of the human spinal NSCs are assessed by engrafting the cells and measuring recovery motor benefit by BBB scoring.
- Example 6 Treatment of Motor Neuron Diseases by Transplantation of Human Spinal NSCs.
- the NSCs of the disclosed methods afford both clinical and biological benefits that are powerful and significant. To this end, the disclosed methods allow for the treatment of conditions both disseminated throughout the central nervous system, such as ALS, as well as localized in a particular area as in spinal cord ischemia described above.
- ALS although grafting in the lumbar cord may omit other vital portions of the segmental motor apparatus, i.e. the cervical motor neuron column responsible for respiratory movements, the disclosed methods of implanting NSCs in the spinal cord facilitate the release of BDNF and GDNF and other factors from the transplanted cells into the CSF where a broader effect on host motor neurons throughout the cord can occur.
- the SODl G93A rat represents a comprehensive model for the neuropathology and clinical symptoms of an especially aggressive form of ALS.
- NSCs from human fetal spinal cord can be grafted into the lumbar cord of SODl G93A rats and mice where extensive differentiation of the neurons occurs and where the differentiated neurons subsequently form synaptic contacts with host neurons and express and release GDNF and BDNF.
- the rat SODl G93A model for example, characterized by fulminant motor neuron disease can be used to study and demonstrate the beneficial effects of NSCs in the disease.
- NSC grafts employed in the disclosed methods survive well in a neurodegenerative environment and exert powerful clinical effects. At least a portion of these effects is related to the ability of these grafts to express and release motor neuron growth factors. Accordingly, the grafted NSCs of the disclosed methods delay the onset and progression of the fuhninant motor neuron disease and extend the life span of these animals by more than ten days, despite the restricted grafting schedule that was limited to the lumbar protuberance.
- Live or dead NSCs are grafted into the lumbar protuberance (L4 & L5) of nine-week old (220-30Og) SODl G93A rats of mixed gender mounted on a Kopf spinal stereotaxic unit under microscopic guidance.
- Dead cells are prepared by repetitive freezing and thawing before grafting.
- Cell suspensions are delivered under aseptic conditions via approximately eight injections aimed at ventral horn on both sides of the ventral horn (5 x 10 4 NSC per injection site, four injection sites per side) with pulled-beveled glass micro-pipettes connected, via silastic tubing, to 10 ⁇ l Hamilton microsyringes. All rats receive FK-506 (1 mg/kg i.p.) to prevent immune rejection based on pilot data indicating that, in untreated animals or animals receiving cyclosporin, graft survival does not exceed one month.
- Rats are tested for motor strength and weight twice weekly. Motor strength tests included the Basso, Beattie and Bresnahan (BBB) locomotor rating scale (Basso et al., 1995), and the inclined plane scale (Rivlin and Tator, 1977).
- BBB score testing animals are tested for about 4 or 5 minutes in the open field. All locomotor performance is recorded and rated according to scale.
- inclined plane testing rats are placed on the incline plane mat, and angle is adjusted to the maximal point at which their position can be stabilized for about 5 seconds. This angle is then recorded as the animal's inclined plane score. BBB and incline plane scores are analyzed by MANOVA followed by Fisher LSD post hoc test.
- Disease onset is defined as the point at which body weight begins to decrease abruptly.
- Course of illness as an effect of graft type (live- or dead-cell graft) is analyzed by comparing age at disease onset and age of death between the two groups (with students' t test) as well as with Kaplan-Meier survival analysis followed by long-rank test.
- Rats are euthanized with perfusion-fixation when their BBB score (see below) is less than 3, a stage at which only one joint has movement or there is no movement at all and the animal is considered moribund.
- Tissues are prepared from animals perfused with 4% neutral-buffered paraformaldehyde.
- the thoraco-lumbar spinal cord segments with attached roots and lumbar nerves are further fixed by immersion in the same fixative for an additional four hours.
- Blocks containing the entire grafted area plus 1 mm border above and below the block are cryoprotected and frozen for further processing.
- L3-S1 roots are processed separately as whole-mount preparations or after separating rootlets with heat-coagulated tips of glass pipettes. Blocks are sectioned at the transverse or sagittal plane (35 ⁇ m).
- NSC survival and differentiation is studied with dual-label immunofluorescence that combines, in most cases, HNu, a human-specific marker, with another cellular marker, and is performed as described in Yan et al., 2004.
- a non-stereological method of counting total number of HNu (+) cells as well as cells dually labeled with HNu and a phenotypic marker on randomly selected high-power (10Ox) fields from our immuno fluorescent preparations is used to study NSC differentiation.
- One field in each of six sections spaced ⁇ 1 mm apart through the grafting area is used from each animal.
- CSF is sampled with a 25 G syringe from the 4th ventricle of animals under gas anesthesia. Tissue samples containing the grafting sites and areas adjacent to those are dissected transversely from 1-mm-thick fresh spinal cord slices. CSF or tissue samples are processed, and total protein is first measured as described in Sheng et al., 2003. Levels of GDNF and BDNF are measured in CSF and spinal cord samples using the E-Max ImmunoAssay system (Promega, Madison, WI). TMB-chromogen absorbance is read at 450 nm.
- Blots are developed with the SuperSignal Chemiluminescent Substrate (Pierce) and exposed to Kodak-XAR film (Eastman Kodak, Rochester, NY). Blots are then striped and re- blotted with /5-actin antibody (1:500, Sigma) and HRP-linked donkey anti-mouse IgG (1:10000, Jackson ImmunoResearch). Immunoreactive bands are analyzed with Bio- Rad Quantity One software (Bio-Rad Laboratories, Hercules, CA). Band density ratios (GDNF or BDNF: ⁇ actin) are calculated per animal and group means are entered for statistical analysis as in the case of ELISA experiments.
- GDNF or BDNF: ⁇ actin Band density ratios
- HNu (+) cells are shown to survive in the ventral horn (A) and to stain, in their vast majority, with neuronal lineage markers such as the microtubule-associated epitope
- HNu human nuclear protein
- NSC-derived neuronal cells with HNu (+) nucleus and TUJ-I (+) cytoplasm are contacted by rat terminals
- preparations stained with TUJ-I and human-specific synaptophysin reveal dense terminal fields of small boutons apposed to host neurons, especially large and small motor neurons.
- a host motor neuron is contacted by a large number of graft-derived boutons.
- Horizontal sections stained for HNu and human NF-70 show a large number of graft-derived axons leaving the graft on the left and coursing preferentially along the white matter of the ventral funiculus.
- BDNF and GDNF Two peptides with classical trophic effects on mammalian motor neurons, [BDNF and GDNF] (Henderson et al., 1994; Koliatsos et al., 1993). Expression and release of GDNF and BDNF in the spinal cord of grafted SODl G93A rats is determined. Cord preparations and CSF samples are evaluated for BDNF and GDNF by Western blotting and ELISA. GDNF concentrations in the parenchyma and CSF of rats grafted with live cells (Ll and L2) and animals grafted with dead cells (C) are determined by ELISA.
- Ll represents concentrations through the grafting site
- L2 reflects concentrations in tissues one segment above or below. Variance among groups is significant and caused by a large difference between Ll or L2 and C groups.
- Difference in CSF concentrations between experimental (live-cell, L) and control (dead-cell, C) groups is also significant by t test.
- ELISA showed a concentration of 0.912 ⁇ 0.050 pg/ ⁇ g at the graft site and 0.819 ⁇ 0.115 pg/ ⁇ g one segment away in the spinal cord of live NSC-grafted animals. In animals grafted with dead NSCs, these concentrations were 0.368 ⁇ 0.026 pg/ ⁇ g in spinal cord segments containing the graft.
- GDNF concentration was 0.027 ⁇ 0.012 pg/ ⁇ l in experimental and 0.006 ⁇ 0.002 pg/ ⁇ l.
- Western blotting also shows a higher normalized GDNF concentration in animals grafted with live NSCs.
- GDNF Western blotting confirms the ELISA pattern of increase by detecting a 16 kDa protein.
- Western blotting also shows a normalized GDNF density of 0.860 ⁇ 0.007 in live-cell grafts and 0.708 ⁇ 0.052 in dead-cell grafts.
- ELISA staining of BDNF in the parenchyma and CSF of experimental rats and controls are determined.
- ELISA analysis shows a concentration of 0.086 ⁇ 0.014 pg/ ⁇ g at the graft site (Ll) and 0.054 ⁇ 0.009 pg/ ⁇ g one segment away from graft in experimental animals (L2).
- the BDNF concentration was 0.010 ⁇ 0.003 pg/ ⁇ g in graft-containing segments.
- the differences between experimental and control CSF concentrations are significant.
- BDNF concentration is 0.041 ⁇ 0.013 pg/ ⁇ l in experimental animals and 0.010 ⁇ 0.008 pg/ ⁇ l in controls.
- Rats with live grafts show an elaboration of pathways originating in the graft and innervating structures in and around the central canal.
- the vast majority of NSC-derived axon terminals innervating the central canal co-localizes with GDNF immunoreactivity.
- Widespread co-localization of human synaptophysin and GDNF is observed within graft-derived terminals innervating ependymal cells in the central canal .
- Example 7 Treatment of traumatic spinal cord injury by transplantation of human spinal cord neural stem/progenitor cells, treatment of syringomyelia.
- the human-derived NSCs formed large cellular aggregates consisting of neurons, astrocytes and oligodendrocytes. These grafts invariably and completely filled each lesion. Iminature-appearing, NeuN+/human nuclei ⁇ neurons often comprised 50% of the donor cell population. These neurons sent human neurofilament+ processes through both gray and white matter for distances of at least 2cm from the graft site.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15156823.5A EP2913393B8 (en) | 2004-11-17 | 2005-11-17 | Transplantation of human neural cells for treatment of neurodegenerative conditions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62922004P | 2004-11-17 | 2004-11-17 | |
PCT/US2005/041631 WO2006055685A2 (en) | 2004-11-17 | 2005-11-17 | Transplantation of human neural cells for treatment of neurodegenerative conditions |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15156823.5A Division EP2913393B8 (en) | 2004-11-17 | 2005-11-17 | Transplantation of human neural cells for treatment of neurodegenerative conditions |
EP15156823.5A Division-Into EP2913393B8 (en) | 2004-11-17 | 2005-11-17 | Transplantation of human neural cells for treatment of neurodegenerative conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1814979A2 true EP1814979A2 (en) | 2007-08-08 |
EP1814979A4 EP1814979A4 (en) | 2008-09-03 |
EP1814979B1 EP1814979B1 (en) | 2015-04-08 |
Family
ID=36407743
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15156823.5A Active EP2913393B8 (en) | 2004-11-17 | 2005-11-17 | Transplantation of human neural cells for treatment of neurodegenerative conditions |
EP05851748.3A Active EP1814979B1 (en) | 2004-11-17 | 2005-11-17 | Transplantation of human neural cells for treatment of neurodegenerative conditions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15156823.5A Active EP2913393B8 (en) | 2004-11-17 | 2005-11-17 | Transplantation of human neural cells for treatment of neurodegenerative conditions |
Country Status (13)
Country | Link |
---|---|
US (6) | US7691629B2 (en) |
EP (2) | EP2913393B8 (en) |
JP (3) | JP5424559B2 (en) |
KR (2) | KR101429284B1 (en) |
CN (2) | CN101084303A (en) |
ES (1) | ES2537004T3 (en) |
HK (1) | HK1202238A1 (en) |
IL (2) | IL183092A (en) |
IN (1) | IN2014CN03629A (en) |
NO (1) | NO340914B1 (en) |
PH (1) | PH12015501195B1 (en) |
RU (2) | RU2434636C2 (en) |
WO (1) | WO2006055685A2 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7838292B1 (en) | 2001-03-29 | 2010-11-23 | University Of Louisville Research Foundation, Inc. | Methods for obtaining adult human olfactory progenitor cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
US8491883B2 (en) * | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
RU2434636C2 (en) | 2004-11-17 | 2011-11-27 | Ньюралстем, Инк. | Transplantation of nerve cells for treatment of neurodegenerative states |
AU2006220696B2 (en) | 2005-03-07 | 2010-08-19 | Sanbio, Inc. | Use of neuronal precursor cells for treatment of central nervous system lesions |
GB0822246D0 (en) | 2008-12-05 | 2009-01-14 | Reneuron Ltd | Composition |
BRPI0923177A2 (en) * | 2008-12-19 | 2020-08-25 | Advanced Technologies And Regenerative Medicine, Llc | uses of compositions to treat neuropathic pain and space, said compositions, and kit |
CA2747794C (en) | 2008-12-19 | 2018-10-30 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of lung and pulmonary diseases and disorders |
GB0902034D0 (en) | 2009-02-06 | 2009-03-11 | Reneuron Ltd | Method |
US10386360B2 (en) | 2009-03-13 | 2019-08-20 | University Of Central Florida Research Foundation, Inc. | Bio-microelectromechanical system transducer and associated methods |
CA2756600C (en) | 2009-03-26 | 2019-08-20 | Advanced Technologies And Regenerative Medicine, Llc | Human umbilical cord tissue cells as therapy for alzheimer's disease |
US8815584B1 (en) | 2009-04-23 | 2014-08-26 | University Of Central Florida Research Foundation, Inc. | Method of co-culturing mammalian muscle cells and motoneurons |
US9163216B1 (en) | 2009-04-23 | 2015-10-20 | University Of Central Florida Research Foundation, Inc. | Method for culturing skeletal muscle for tissue engineering |
US8828721B1 (en) | 2009-05-28 | 2014-09-09 | University Of Central Florida Research Foundation, Inc. | Method of myelinating isolated motoneurons |
US9404140B1 (en) | 2009-11-03 | 2016-08-02 | The University Of Central Florida Research Foundation, Inc. | Patterned cardiomyocyte culture on microelectrode array |
US9489474B2 (en) | 2010-02-05 | 2016-11-08 | University Of Central Florida Research Foundation, Inc. | Model and methods for identifying points of action in electrically active cells |
EP2585171B1 (en) | 2010-04-23 | 2018-12-26 | University Of Central Florida Research Foundation, Inc. | Formation of neuromuscular junctions in a defined system |
SG187226A1 (en) * | 2010-07-28 | 2013-03-28 | Neuralstem Inc | Methods for treating and/or reversing neurodegenerative diseases and/or disorders |
US9498554B2 (en) | 2012-07-24 | 2016-11-22 | S.C. Johnson & Son, Inc. | Dispensing device |
US10357517B1 (en) | 2012-10-01 | 2019-07-23 | University Of South Florida | Methods of treating epilepsy using neural stem cells that express nanog, SSEA-4, OCT-4, MIR-34B, MIR-34C and MIR-592 |
RU2515475C1 (en) * | 2012-11-15 | 2014-05-10 | Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК | Method for stimulation of endometrial decidua formation experimentally |
US10694747B2 (en) | 2012-11-21 | 2020-06-30 | S. C. Johnson & Son, Inc. | Dispenser comprising only one single hinge |
US20150369791A1 (en) | 2013-01-30 | 2015-12-24 | University Of Central Florida Research Foundation, Inc. | Devices and systems for mimicking heart function |
WO2014138003A1 (en) * | 2013-03-04 | 2014-09-12 | Neuralstem, Inc. | Compositions comprising an immunosuppressive drug and/or neural stem cells and methods of using same for the treatment of neurodegenerative diseases and/or disorders |
WO2014176606A1 (en) | 2013-04-26 | 2014-10-30 | Memorial Sloan-Kettering Center Center | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells |
CN104278008B (en) | 2013-07-12 | 2020-08-21 | 北京宏冠再生医学科技有限公司 | Method, kit and application for preparing pluripotent stem cells through small molecule compound treatment |
US10947500B2 (en) * | 2014-06-27 | 2021-03-16 | Angiocrine Bioscience, Inc. | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same |
KR101675123B1 (en) * | 2014-06-27 | 2016-11-14 | 연세대학교 산학협력단 | A Composition for Treating Ischemic Diseases or Neuroinflammatory Diseases Comprising PSA-NCAM-positive Neural Precursor Cells as Active Ingredient |
US10935541B2 (en) | 2014-08-07 | 2021-03-02 | University Of Central Florida Research Foundation, Inc. | Devices and methods comprising neuromuscular junctions |
KR20190060016A (en) | 2014-10-20 | 2019-05-31 | 뉴럴스템, 인크. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
US10286009B2 (en) * | 2015-05-16 | 2019-05-14 | Asterias Biotherapeutics, Inc. | Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury |
AU2016305705B2 (en) | 2015-08-13 | 2019-06-13 | Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. | Induced extended pluripotent stem cells, methods of making and using |
WO2017091943A1 (en) | 2015-11-30 | 2017-06-08 | Hong Guan Ltd. | Improved methods for reprograming non-pluripotent cells into pluripotent stem cells |
KR101865404B1 (en) * | 2016-02-05 | 2018-06-07 | 경북대학교 산학협력단 | Composition for preventing or treating neurodegenerative disease comprising stem cell overexpressing VEGF |
US11920155B2 (en) | 2016-03-30 | 2024-03-05 | Asterias Biotherapeutics, Inc. | Oligodendrocyte progenitor cell compositions |
FR3058892B1 (en) * | 2016-11-23 | 2021-04-09 | Univ Bordeaux | NEURAL TISSUE UNIT AND USE OF SUCH UNIT FOR IMPLEMENTATION IN THE NERVOUS SYSTEM OF A MAMMAL |
CN106619722A (en) * | 2016-12-05 | 2017-05-10 | 上海安集协康生物技术股份有限公司 | Neural stem cell injection for treating brain damage disease |
JP6500051B2 (en) * | 2017-03-17 | 2019-04-10 | 哲丸 村田 | Tissue processing method |
WO2018218480A1 (en) | 2017-05-31 | 2018-12-06 | Beihao Stem Cell And Regenerative Medicine Research Institute Co., Ltd. | Methods for chemically induced lineage reprogramming |
EP3914264A4 (en) | 2019-01-23 | 2022-11-23 | Asterias Biotherapeutics, Inc. | Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells |
CN111494422B (en) * | 2019-01-29 | 2022-04-29 | 中国科学院遗传与发育生物学研究所 | Product for treating spinal cord injury and application thereof |
US20230082155A1 (en) * | 2019-12-27 | 2023-03-16 | Rainbow Inc. | Integrated system for safe intracranial administration of cells |
CN115166260B (en) * | 2022-07-11 | 2023-06-13 | 东南大学 | Application of vitamin D binding protein in exosome derived from blood plasma brain cells in diagnosis of depression |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0233838A3 (en) | 1986-02-04 | 1990-01-31 | Incyte Pharmaceuticals, Inc. | Neurite-promoting factor and process for the manufacture thereof |
US4753635A (en) | 1986-05-23 | 1988-06-28 | Jacqueline Sagen | Inducing analgesia by implantation of cells releasing neuroactive substances |
NZ226750A (en) | 1987-10-29 | 1990-09-26 | Amrad Corp Ltd | Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene |
DE68928914T2 (en) | 1988-08-04 | 1999-09-09 | Amrad Corp. Ltd. | (IN VITRO) PROPAGATION OF EMBRYONIC STEM CELLS USING LEUKEMIA INHIBITION FACTOR (LIF) |
US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US4980174A (en) | 1988-12-23 | 1990-12-25 | Jacqueline Sagen | Method for alleviating depression |
AU6174490A (en) | 1989-08-04 | 1991-03-11 | Board Of Regents, The University Of Texas System | Methods and compositions; purified preparation of neural progenitor regulatory factor |
WO1991009936A1 (en) | 1989-12-26 | 1991-07-11 | Hana Biologics, Inc. | Proliferated neuron progenitor cell product and process |
US5411883A (en) | 1989-12-26 | 1995-05-02 | Somatix Therapy Corporation | Proliferated neuron progenitor cell product and process |
US5196315A (en) | 1990-05-01 | 1993-03-23 | The Johns Hopkins University | Human neuronal cell line |
US5612211A (en) | 1990-06-08 | 1997-03-18 | New York University | Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors |
US5851832A (en) | 1991-07-08 | 1998-12-22 | Neurospheres, Ltd. | In vitro growth and proliferation of multipotent neural stem cells and their progeny |
US7361505B1 (en) | 1991-07-08 | 2008-04-22 | Neurospheres Holdings Ltd. | Multipotent neural stem cell compositions |
US5750376A (en) * | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
US6399369B1 (en) | 1991-07-08 | 2002-06-04 | Neurospheres Holdings Ltd. | Multipotent neural stem cell cDNA libraries |
US5981165A (en) * | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | In vitro induction of dopaminergic cells |
EP0594669B9 (en) | 1991-07-08 | 2008-03-19 | NeuroSpheres Holdings Ltd. | Growth factor-responsive neural progenitor cells which can be proliferated in vitro. |
US6294346B1 (en) | 1991-07-08 | 2001-09-25 | Neurospheres Holdings, Ltd. | Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents |
US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
US6071889A (en) | 1991-07-08 | 2000-06-06 | Neurospheres Holdings Ltd. | In vivo genetic modification of growth factor-responsive neural precursor cells |
EP0755682A1 (en) * | 1991-07-10 | 1997-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of treatment of motor neuron diseases using members of the BDNF/NT-3/NGF family of molecules |
US5175103A (en) | 1991-10-21 | 1992-12-29 | Trustees Of University Of Pennsylvania | Preparation of pure cultures of post-mitotic human neurons |
JP4101284B2 (en) | 1991-11-22 | 2008-06-18 | ジェネンテック・インコーポレーテッド | TGF-BETA to improve nerve damage |
US5672499A (en) | 1992-07-27 | 1997-09-30 | California Institute Of Technology | Immoralized neural crest stem cells and methods of making |
US5849553A (en) | 1992-07-27 | 1998-12-15 | California Institute Of Technology | Mammalian multipotent neural stem cells |
NZ256154A (en) | 1992-07-27 | 1997-02-24 | California Inst Of Techn | Production of mammalian multipotent neural stem cells, antibodies |
US5589376A (en) | 1992-07-27 | 1996-12-31 | California Institute Of Technology | Mammalian neural crest stem cells |
WO1994003199A1 (en) | 1992-08-04 | 1994-02-17 | Regeneron Pharmaceuticals, Inc. | Method of enhancing differentiation and survival of neuronal precursor cells |
AU4950393A (en) | 1992-08-19 | 1994-03-15 | Richard Kroczek | Dna sequence encoding a novel member of the steroid and thyroid hormone receptor family |
AU5367694A (en) | 1992-10-28 | 1994-05-24 | Neurospheres Holdings Ltd | Biological factors and neural stem cells |
WO1995013364A1 (en) | 1993-11-09 | 1995-05-18 | Neurospheres Holdings Ltd. | In situ modification and manipulation of stem cells of the central nervous system |
WO1996009543A1 (en) | 1994-09-23 | 1996-03-28 | Neurospheres Holdings Ltd. | In vitro models of cns function and dysfunction |
CN1170435A (en) | 1994-11-14 | 1998-01-14 | 纽罗斯菲里斯控股有限公司 | Regulation of neural stem cell proliferation |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5735505A (en) * | 1995-04-03 | 1998-04-07 | Data Connections, Inc. | Cable pulley device and method |
US5753505A (en) | 1995-07-06 | 1998-05-19 | Emory University | Neuronal progenitor cells and uses thereof |
US5770414A (en) | 1996-02-20 | 1998-06-23 | The Regents Of The University Of California | Regulatable retrovirus system for genetic modification of cells |
US5753506A (en) | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
JP3467154B2 (en) * | 1996-10-14 | 2003-11-17 | パロマ工業株式会社 | Absorption air conditioner |
AU7258098A (en) | 1997-04-24 | 1998-11-13 | California Institute Of Technology | Methods for differentiating neural stem cells |
WO1999001159A1 (en) | 1997-07-04 | 1999-01-14 | University Of Utah Research Foundation | Lineage-restricted neuronal precursors |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US5932473A (en) * | 1997-09-30 | 1999-08-03 | Becton Dickinson And Company | Preparation of a cell culture substrate coated with poly-D-lysine |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
JP4709382B2 (en) * | 1998-09-22 | 2011-06-22 | ニューラルステム バイオファーマシューティカルズ、リミテッド | Stable neural stem cell line |
US6284539B1 (en) | 1998-10-09 | 2001-09-04 | Neuralstem Biopharmaceuticals, Ltd. | Method for generating dopaminergic cells derived from neural precursors |
US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
HN2001000224A (en) | 2000-10-19 | 2002-06-13 | Pfizer | IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI - INFLAMMATORY AND ANALGESIC AGENTS. |
TWI245764B (en) | 2001-04-23 | 2005-12-21 | Hank F Kung | Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
WO2003000852A2 (en) | 2001-06-22 | 2003-01-03 | The University Of Texas System | Method of producing region-specific neurons from human neuronal stem cells |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
WO2003046141A2 (en) * | 2001-11-26 | 2003-06-05 | Advanced Cell Technology, Inc. | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
WO2004072264A2 (en) * | 2003-02-12 | 2004-08-26 | Johns Hopkins University School Of Medicine | Fate determination by hes 1 in hematopoietic stem-progenitor cells and uses thereof |
RU2434636C2 (en) * | 2004-11-17 | 2011-11-27 | Ньюралстем, Инк. | Transplantation of nerve cells for treatment of neurodegenerative states |
WO2008002250A1 (en) | 2006-06-30 | 2008-01-03 | Elena Kozlova | Improved stem cells for transplantation and methods for production thereof |
SG187226A1 (en) * | 2010-07-28 | 2013-03-28 | Neuralstem Inc | Methods for treating and/or reversing neurodegenerative diseases and/or disorders |
-
2005
- 2005-11-17 RU RU2007122507/14A patent/RU2434636C2/en not_active IP Right Cessation
- 2005-11-17 KR KR1020077012097A patent/KR101429284B1/en active IP Right Grant
- 2005-11-17 KR KR1020137020263A patent/KR101505347B1/en active IP Right Grant
- 2005-11-17 EP EP15156823.5A patent/EP2913393B8/en active Active
- 2005-11-17 EP EP05851748.3A patent/EP1814979B1/en active Active
- 2005-11-17 US US11/281,640 patent/US7691629B2/en active Active
- 2005-11-17 JP JP2007543219A patent/JP5424559B2/en not_active Expired - Fee Related
- 2005-11-17 WO PCT/US2005/041631 patent/WO2006055685A2/en active Application Filing
- 2005-11-17 ES ES05851748.3T patent/ES2537004T3/en active Active
- 2005-11-17 CN CNA2005800394500A patent/CN101084303A/en active Pending
- 2005-11-17 CN CN201410240718.8A patent/CN104042629A/en active Pending
- 2005-11-17 IN IN3629CHN2014 patent/IN2014CN03629A/en unknown
-
2007
- 2007-05-09 IL IL183092A patent/IL183092A/en active IP Right Grant
- 2007-06-15 NO NO20073078A patent/NO340914B1/en not_active IP Right Cessation
-
2009
- 2009-03-16 US US12/404,841 patent/US8460651B2/en active Active
-
2010
- 2010-02-22 US US12/710,097 patent/US8236299B2/en not_active Expired - Fee Related
- 2010-03-08 IL IL204356A patent/IL204356A/en active IP Right Revival
-
2011
- 2011-07-28 RU RU2011131830/15A patent/RU2011131830A/en not_active Application Discontinuation
-
2012
- 2012-02-02 JP JP2012020641A patent/JP5805551B2/en active Active
-
2013
- 2013-05-09 US US13/890,787 patent/US9220730B2/en active Active
-
2014
- 2014-12-25 JP JP2014262195A patent/JP5981526B2/en not_active Expired - Fee Related
-
2015
- 2015-03-17 HK HK15102713.5A patent/HK1202238A1/en unknown
- 2015-05-28 PH PH12015501195A patent/PH12015501195B1/en unknown
- 2015-11-30 US US14/954,105 patent/US9744194B2/en active Active
-
2017
- 2017-07-27 US US15/661,281 patent/US10286010B2/en active Active
Non-Patent Citations (9)
Title |
---|
CUMMINGS BRIAN J ET AL: "Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 39, September 2005 (2005-09), pages 14069-14074, XP002488035 ISSN: 0027-8424 * |
FUJIWARA YASUSHI ET AL: "Intravenously injected neural progenitor cells of transgenic rats can migrate to the injured spinal cord and differentiate into neurons, astrocytes and oligodendrocytes" NEUROSCIENCE LETTERS, vol. 366, no. 3, 19 August 2004 (2004-08-19), pages 287-291, XP002488036 ISSN: 0304-3940 * |
JAIN MEENA ET AL: "GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro." EXPERIMENTAL NEUROLOGY, vol. 182, no. 1, July 2003 (2003-07), pages 113-123, XP002488034 ISSN: 0014-4886 * |
LEPORE A C ET AL: "Neural precursor cells can be delivered into the injured cervical spinal cord by intrathecal injection at the lumbar cord" BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1045, no. 1-2, 31 May 2005 (2005-05-31), pages 206-216, XP004904364 ISSN: 0006-8993 * |
LLADO J ET AL: "Neural stem cells protect against glutamate-induced excitotoxicity and promote survival of injured motor neurons through the secretion of neurotrophic factors" MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, vol. 27, no. 3, 1 November 2004 (2004-11-01), pages 322-331, XP004613831 ISSN: 1044-7431 * |
MARSALA MARTIN ET AL: "Spinal implantation of hNT neurons and neuronal precursors: graft survival and functional effects in rats with ischemic spastic paraplegia" EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 20, no. 9, 12 October 2004 (2004-10-12), pages 2401-2414, XP002488033 ISSN: 0953-816X * |
OKA S ET AL: "Autologous transplantation of expanded neural precursor cells into the demyelinated monkey spinal cord" BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1030, no. 1, 5 November 2004 (2004-11-05), pages 94-102, XP004657006 ISSN: 0006-8993 * |
RAPPA G ET AL: "Efficient expansion and gene transduction of mouse neural stem/progenitor fibronectin cells on recombinant", 20040101; 20040000, vol. 124, no. 4, 1 January 2004 (2004-01-01), pages 823-830, XP002299557, * |
See also references of WO2006055685A2 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10286010B2 (en) | Methods of treating neurodegenerative conditions | |
US7632680B2 (en) | Compositions and methods for isolation, propagation, and differentiation of human stem cells and uses thereof | |
EP2598154B1 (en) | Methods for treating and/or reversing neurodegenerative diseases and/or disorders | |
ES2776356T3 (en) | Human neural cell transplantation for the treatment of neurodegenerative conditions | |
Lu et al. | Stem Cells for Spinal Cord Injury | |
Park et al. | Neural Stem Cells and Transplant Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070522 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VELARDO, MARGARET J. Inventor name: YAN, JUN Inventor name: JOHE, KARL K. Inventor name: KOLIATSOS, VASSILIS Inventor name: MARSALA, MARTIN Inventor name: REIER, PAUL J. Inventor name: KAKINOHAMA, OSAMU Inventor name: HAZEL, THOMAS G. |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080804 |
|
17Q | First examination report despatched |
Effective date: 20081128 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602005046291 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C12N0005000000 Ipc: C12N0005079700 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 5/0797 20100101AFI20140829BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20141029 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HAZEL, THOMAS G. Inventor name: MARSALA, MARTIN Inventor name: YAN, JUN Inventor name: REIER, PAUL J. Inventor name: KOLIATSOS, VASSILIS Inventor name: JOHE, KARL K. Inventor name: VELARDO, MARGARET J. Inventor name: KAKINOHAMA, OSAMU |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NEURALSTEM, INC. |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 720594 Country of ref document: AT Kind code of ref document: T Effective date: 20150515 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602005046291 Country of ref document: DE Effective date: 20150521 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2537004 Country of ref document: ES Kind code of ref document: T3 Effective date: 20150601 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SERVOPATENT GMBH, CH |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 720594 Country of ref document: AT Kind code of ref document: T Effective date: 20150408 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20150408 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150808 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150709 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602005046291 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150408 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 |
|
26N | No opposition filed |
Effective date: 20160111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20160929 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20160926 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20161115 Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20051117 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150408 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171117 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20181228 Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: SENECA BIOPHARMA, INC., US Free format text: FORMER OWNER: NEURALSTEM, INC., US |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602005046291 Country of ref document: DE Representative=s name: HANNKE BITTNER & PARTNER, PATENT- UND RECHTSAN, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602005046291 Country of ref document: DE Owner name: SENECA BIOPHARMA, INC. (N.D.GES.D. STAATES DEL, US Free format text: FORMER OWNER: NEURALSTEM, INC., GERMANTOWN, MD., US |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: SENECA BIOPHARMA, INC. Effective date: 20200424 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: WANNERSTRASSE 9/1, 8045 ZUERICH (CH) |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191130 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191118 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230516 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231127 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231201 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20231127 Year of fee payment: 19 Ref country code: FR Payment date: 20231127 Year of fee payment: 19 Ref country code: DE Payment date: 20231129 Year of fee payment: 19 |